Interleukin-10 and Its Application Exploration in Immunotherapy

Please register via: https://us06web.zoom.us/webinar/register/WN_UohabTfdQJOhEF0YTMQIEA#/registration

Abstract: Cytokine therapy has been explored for treating various indications for decades, but its clinical advancement has been very slow. This is primarily due to the complicated mechanisms of cytokines’ action, significant clinical toxicity, and the difficulty in maintaining a safe and effective therapeutic window. Mr. Lu’s research has focused on the modification and optimization of IL-10. Through modification with protein engineering approaches, Mr. Lu and team have significantly reduced the clinical toxicity associated with IL-10. Furthermore, different modification strategies have been devised to tailor the engineered IL-10 for the treatment of either tumors (e.g., with PD1-IL10) or autoimmune diseases (e.g., with TL1A-IL10), respectively.

Mr. Lu Di obtained his bachelor’s and master’s degrees from Huazhong Agricultural University in China. Since graduation, Mr. Lu has been engaged in drug research and development in the industry. He has successively worked at YZY-BIO, Wuhan Healthgen Biotechnology Corp., Ltd., and Fapon biopharma, accumulating years of experience in biologics design, modification and optimization, and manufacturing. Currently, he is the Head of R&D at Fapon biopharma, where he is responsible for establishing the entire R&D management system, formulating strategic plans, recruiting and managing teams, leading early-stage R&D project initiation, antibody discovery, and the construction of protein engineering technology platforms. Mr. Lu is the inventor of more than 50 patents. Mr. Lu’s technical expertise focuses on protein engineering modification and translational application. He has led the construction of multiple technology platforms and the initiation and R&D of product projects, including the Fibody Bispecific Antibody Platform, IL-10 Product Platform, and TCE Product Platform. Among these, FP008 (PD1-IL10M), the project with the fastest progress, is currently in Phase 1 clinical development.